'The Start of a Process, Not the Cure': What Psychedelic Trial Participants Want Practitioners to Know

Most of what practitioners learn about psychedelic-assisted therapy comes from the clinician's side of the room: protocols, rating scales, safety checklists. A new study published on 14 October 2026 in Frontiers in Psychiatry turns the lens around. Researchers from King's College London and Beckley Psytech worked with the Psychedelic Participant Advocacy Network (PsyPAN), a UK-based group of more than 70 former trial participants, to ask a simple question: what did people who actually went through these trials wish had been done differently?

The answers are modest in scale but unusually practical, and they speak directly to anyone training to deliver this kind of care in Canada.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334.

What the study did

The authors ran three remote focus groups and a one-day in-person workshop with four PsyPAN members, each of whom had previously taken part in at least one psychedelic clinical trial. Three had joined treatment-resistant depression studies involving psilocybin or DMT, and one had participated in a psilocybin study for an eating disorder. Transcripts were analysed using reflexive thematic analysis, a standard qualitative method, and the discussions also drew on the broader experience of PsyPAN's membership. Participants were paid for their time, and none had been enrolled in a Beckley Psytech-sponsored study.

The sample is small, and three of the four authors are affiliated with a company developing psychedelic medicines, so this is best read as structured lived-experience input rather than a representative survey. That said, the themes it surfaces are the ones practitioners keep running into.

Five themes practitioners should take seriously

People come looking for a treatment and find a clinical trial. Participants enrolled hoping for relief, then met randomisation, blinding, fixed schedules, and strict eligibility rules that often felt at odds with that hope. The authors argue that clear communication during recruitment and screening, and a deliberate separation of the "research" frame from the "treatment" frame, reduces disappointment later.

"Set and setting" begins long before dosing. The study extends the familiar concept to the whole trial journey. First impressions during recruitment set the tone, staff conduct shaped how safe people felt, and time-limited support and the ending of the study were experienced as part of the setting too. As one participant put it, "The therapeutic relationship doesn't start the moment the person has taken a substance."

Facilitators act as mediators. During dosing sessions, facilitators had to balance protocol requirements with participants' emotional and physical needs in real time. Participants described trust, the willingness to surrender to the experience, and support in moving through difficult moments as hinging on the facilitator's presence. Explicit agreements about physical touch and movement, made in advance, helped people feel safe enough to engage.

Dosing is the beginning, not the end. Participants consistently described the session as the start of an ongoing process of meaning-making and change. One summarised it as "the start of a process, and certainly not the cure." Change arrived unevenly, and some found rapid shifts hard to manage without support.

Support needs do not end when the study does. Experiences after study completion varied, with some participants reporting loss, grief, or frustration, and "limited access to psychedelically informed care." All four said more structured support would have helped, and the group advocated for independent, trial-specific peer support.

Why this matters in Canada

Canada's clinical psychedelic landscape still runs largely through regulated channels: Health Canada-authorised clinical trials, case-by-case federal authorisation initiated by a physician, and ketamine-assisted therapy delivered under provincial college oversight. In every one of those settings, patients can encounter the same mismatch the PsyPAN participants described, where someone seeking help meets a protocol built for evidence generation or a one-off authorisation rather than ongoing care.

That makes the study's recommendations unusually relevant for Canadian teams. Managing expectations before a session, agreeing touch boundaries in advance, keeping staff continuity, involving a patient's support network, and planning for integration and for the end of care are not drug-specific skills. They are the core competencies of the preparation, dosing-support, and integration roles that nurses, psychologists, physicians, and psychotherapists are increasingly being asked to fill.

The authors are candid that "scientific, regulatory and resource constraints" limit how far these practices can be adopted, and a four-person focus group cannot tell us how common any single experience is. But the direction of travel is clear: as regulators in Canada and abroad move toward decisions on psychedelic medicines, the question of what good delivery looks like is shifting from trial design to clinical practice, and patients are asking to be part of answering it.

What this means for practitioners

For clinicians considering or pursuing psychedelic-therapy training, the practical takeaways are concrete. Build preparation sessions around expectations as much as logistics. Treat consent to touch as an explicit, revisited agreement rather than an assumption. Plan integration as a process with a defined but flexible arc, and think early about what happens when your involvement ends, including whether peer support is available. Each of these is a teachable, assessable skill.

ATMA CENA's Advanced Pathways are complete programs that begin with the Psychedelic Therapy Foundations course and build toward supervised practice, with most coursework delivered online and the KAT Immersive offered in person in Calgary. If you are weighing how this kind of training fits your scope of practice, you can explore the programs at the training page or book a conversation with a program advisor.

Sources

1. Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network. Frontiers in Psychiatry, Volume 17, 2026.
2. Participant Advocacy Insights for Psychedelic Trials: UK & Global Policy Implications. The Psychedelic Journal, 2026.